(24/7 MARKET NEWS) – IVERIC bio, Inc. (NASDAQ: ISEE) announced positive topline results from GATHER2, the Company’s second Phase 3 clinical trial of Zimura® (avacincaptad pegol), a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA). GATHER2 this morning.
IVERIC eclipsed the $14 mark and pulled back to $13.06, up $3.62 (+38.35%), on over 900 thousand shares traded.
Key inflection points are just above $12 and $14.
Please go to the following link for further details https://www.businesswire.com/news/home/20220905005451/en/
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.